FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
Related Stories
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 21 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 27 days
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 7 wks
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 7 wks
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 1 month
Common asthma drug may overcome immunotherapy resistance in cancers / 2 months
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Diagnostics, Hospital Operations, Public Health, Diabetes and look for the RSS link.
StackHealth Time Machine